AMGNAmgen Inc.

“In clinical development, we have designed and implemented a proprietary site selection model that improves clinical trial enrollment with a significant and in some cases, up to threefold improvement in enrollment rates.”

“In AI-enabled automation, it has reduced production line clearance time at one of our manufacturing sites from approximately 30 minutes to about 2 minutes per batch run.”

“Antibody lead optimization has accelerated by 50% from contributions both to lead discovery and lead optimization.”

“Integrated multi-omics data resources at Amgen deCODE Genetics identify new targets for therapeutic consideration, in particular, within noncoding regions of the human genome studied at population scale.”

“Leveraging large language models and Agentic AI for regulatory filing preparation, we are seeing early promising results in data ingestion, integration and document drafting.”

“Over the last several years, amidst the rapid advances in artificial intelligence, we've taken a principled approach to reconsidering and augmenting drug discovery and therapeutic development. At the intersection of powerful AI models developed both externally and internally with Amgen research and insight-rich proprietary data sets, we are beginning to see meaningful tangible advances across Amgen R&D.”

“we took steps early on to have Dave Reese lead these efforts, and we're grateful to him for the success he's achieved with this initiative. And we're encouraged that Jay Bradner will build on Dave's accomplishments, leading our artificial intelligence and data activities across the company.”

“recognizing long ahead of many others the growing importance of AI and what he called the Hinge moment, Dave both raised his hand to be Amgen's first Chief Technology Officer and helped attract Jay Bradner to be his successor as Head of R&D.”

“With the retirement of our revered and beloved colleague, David Reese, I'm excited to lead the AI and data transformation across our business at the enterprise level, working in partnership with our leadership, staff and collaborators.”

“We've talked about the excitement we feel about the convergence of technology and biology, including the application of artificial intelligence across the company. Here, too, we're making great progress. And there's no question we're in a period of tremendous change, and we're encouraged by the progress we're making in embedding new capabilities.”

“These are early innings, but we are captivated by the potential for AI and data science to deliver measurable impact and value in R&D and across the enterprise, as Peter will highlight in a few moments.”

“we're thrilled, excited about the progress that we made in artificial intelligence and data under Dave's leadership as well as the other businesses that Dave has had responsibility for.”

“We see technology and artificial intelligence as increasingly important tools to help Amgen operate with greater speed, productivity and scale across the enterprise.”

“We are also seeing promising results as our colleagues across Amgen use AI to enhance productivity.”